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INTRODUCTION 
In 1960 Nowell and Hungerford^ discovered that dividing cells in the 
bone marrow of patients with chronic myelogenous leukemia (CML) are 
characterized by a deletion in the long arm of one of the group G 
chromosomes, and this marker became known as the Philadelphia (Ph1) 
chromosome. Until the advent of the banding techniques, the identity of 
this chromosome was unknown, but Rowley has since established that the 
Ph' chromosome is not a deletion but a balanced reciprocal translocation 
2 3 between the long arms of chromosomes No. 9 and 22. * Translocations 
involving the No. 22 chromosome and chromosomes other than No. 9 have 
3 
also been observed in a small number of patients with Ph positive CML . 
Because of its presence in erythrocyte, megakaryocyte, granulocyte, and 
monocyte precursors, leukemic transformation is considered to take place 
4 5 in an ancestral cell common to these myeloid cell types. ’ 
There is now strong evidence pointing to a uniclonal origin of the Ph1 
positive leukemic clone. Patients with CML who are heterozygous for 
7 
the enzyme glucose 6-phosphate dehydrogenase ’ , and two patients with sex 
8 9 
chromosome mosaicism, * were found to have the Ph' chromosome restricted 
to just one of their dual cell lines, strongly suggesting that the Ph1+ 
stemline arises from a single cell. Although many investigators have 
found only Ph'+ cells in colonies growing in semi-solid media derived from 
marrow and peripheral blood of patients with CML,^’^Chervenick et al 
found that some patients had both Ph'+ and Ph'- colonies, but no mixed 
colonies, indicating that populations of both normal and leukemic cells 
exist in the marrow of at least some patients with CML. 
The defect is an acquired one, since the Ph1 chromosome is not found 
in the lymphocytes5 nor in fibroblasts of skin^3 or marrow^4 and 

2 
monozygous twins of patients with CML do not have Ph'+ cells in their 
marrows^5-^. Only rare instances of familial occurrence have been 
. .20 
reported 
The Ph1 chromosome is found in the marrow of about 85% of patients 
21 
with CML, but not all patients with the Ph' marker have it in 100% of 
marrow metaphases at diagnosis. Sakurai et al. have suggested that patients 
22 
with some normal cells at diagnosis may survive longer. Two interesting 
23 24 
examples are patients reported by Gatti and Canellos , both of whom had 
some normal metaphases at diagnosis of Ph'+ CML. Both were followed for 
five years before chemotherapy was instituted. 
The literature contains isolated reports of patients with reduced 
populations of Ph'+ cells after therapy of chronic phase CML, and many of 
these patients are among the long survivors (7 to 17 years) in Busulfan - 
25-35 treated series. Seven patients were reported with reduced Ph'+ cells 
on examination 3 to 16 years after diagnosis and there are two reports of 
29 35 
complete absence of the marker at 9 and 13 years. All of these 
29 32 35 patients were treated with Busulfan, some to marrow hypoplasia ’ ’ and 
33 34 
others not so intensively. * There have also been a few reports of 
reduction in Ph'+ cells with treatment other than busulfan (i.e., P , 
6-mercaptopurine (6-MP), methotrexate (MTX), vincristine (VCR), and 
36-39 3p prednisone) . One of these latter patients survived 24 months and the 
other, who was seen at Memorial Hospital, survived 13 months, with transient 
39 
complete loss of the Ph'+ marker from the marrow. 
In 1924, the median survival of untreated CML patients was reported by 
40 Minot et al. to be 31 months from onset of symptoms. Since then, 
therapeutic attempts to improve survival have been generally disappointing; 
median survivals from diagnosis of from 1% to 3^ years have been reported 
on ai An An 
in several large series ’ ’ ’ ’ , and there has been little improvement 
in survival after onset of blastic transformation. 

3 
44 The retrospective study by Monfardini et al. of all CML patients 
seen at Memorial Sloan-Kettering Cancer Center from 1948 through 1967 
revealed an overall median survival from diagnosis of 31 months, with a 
32 longer median (47 months) for the 19 patients who received P , splenic 
irradiation and chemotherapy. Because conventional treatment had not 
appreciably extended survival in almost 50 years, it was decided that a 
more aggressive therapeutic approach to treating early CML might be 
beneficial. 
In recent years attention has focused on the role of the spleen in 
CML. Both the Ph' chromosome and additional stemlines, which characterize 
45 46 progression of the disease, have been noted in the spleen ’ , and a few 
reports have suggested that both these markers may be seen in the spleen 
before the marrow^-^. Armenta et al reported a patient with a long 
history of polycythemia vera whose disease changed to CML in blastic 
transformation; the Ph' chromosome was found in the spleen and lymph nodes 
but not in the marrow or peripheral blood when examined up to 5 months later. 
There are also several reports of more typical cases of CML in which 
49-51 blastic transformation first appears to have occurred in the spleen 
52 53 
or other extra-medul1 ary sites ’ . Loss of aneuploidy as well as decrease 
in the percentage of Ph'+ cells have been noted with remission of blastic 
37-39 54-56 
crisis induced by chemotherapy ’ . There has been one report of 
response to splenectomy which resulted in loss of hyperdiploidy and reduction 
of the Ph'+ metaphasesr from 100% to 23%, with survival of 3 years after 
transformati on.5*’^ 
The therapeutic program, the L-5 Protocol, was designed to include 
early splenectomy (Fig. 1). It was reasoned that splenectomy would remove 
a large mass of leukemic cells and eliminate a potential site for blastic 
transformation, and,in addition, obviate the late complications of massive 
splenic enlargement and hypersplenism. Irradiation was administered prior 
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to splenectomy to reduce the size of the spleen and to control the 
leukocyte and platelet counts, because elevated levels may be associated 
with hemorrhagic and/or thromboembolic complications during or following 
surgical procedures. 
It was further reasoned that drugs which are only effective against 
proliferating cells should be selectively lethal to the Ph'+ cells which 
have an (undefined) pro!iferative advantage5^. Arabinosylcytosine (Ara-C) 
and 6-thioguanine (TG) were chosen as the primary chemotherapy because 
this combination had been found to have at least some selectivity of action 
59 in acute myelogenous leukemia (AML) ; three courses were given, because 
fin 
some patients with AML required three courses before achieving remission . 
It had previously been shown that L-Asparaginase destroyed leukemic cells 
in CML with fair regularity and that it had relatively little effect on 
61 
normal hematopoiesis , and thus this drug was added to the regimen to 
further reduce the leukemic population. The decision regarding further 
treatment depended on the results of chromosome analysis at the end of the 
intensive phase of treatment. 
MATERIALS AND METHODS 
Patient Population 
Between January 1970 and July 1976, 37 adults with Ph'+ CML were 
entered on the L-5 Protocol. Patients were excluded if they were more than 
60 years old, if they were considered to be poor operative risks or too 
unreliable to follow the portocol, or if they elected to receive 
conventional treatment after being told that the L-5 Protocol was 
experimental. Initially, patients were also excluded if they were thought 
to be undergoing blastic transformation, but later two (No.31 and 37) were 
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entered to determine whether there would be any beneficial effect on 
advanced disease. Previously untreated patients were preferred, but some 
patients with prior therapy were accepted if there were none of the 
contraindications listed above. There were 26 males and 11 females ranging 
in age from 16 to 52 years; the median age was 33. 
Tables 1 and 2 show the hematologic status of each patient at the time 
of beginning the protocol. Sixteen had received no prior treamtment, 
except for short-term 1eukepheresis in three. Fifteen had had prior 
Busulfan; the duration of treatment was 4 months or less, except in two 
patients who had received Busulfan for 12 and 24 months. One patient had 
received 6-MP, MTX, and splenic irradiation (300 rads). Six patients were 
given Ara-C, either by continuous 24-hour infusion, or every twelve hours 
with TG (one patient), just prior to starting the protocol, because of very 
/ 9 , high leukocyte counts (160 to 548 x 10 /l) and the clinical necessity of 
rapidly reducing th^se counts. Three of the latter patients presented 
62 
with priapism which resolved after the Ara-C infusions . 
The number of Ph'+ cells present in the marrow of each patient before 
beginning the L-5 Protocol is shown in Tables 1 and 2. All patients 
initially had normal 46 stemlines except Patient 26, who had both 46 and 47 
stemlines. Hyperdiploidy has been reported to herald blastic transfor- 
21 22 49 56 
mation, ’ ’ ’ but this did not occur in her case until 29 months after 
this was first noted. All but three patients initially showed 75-100% 
Ph'+ metaphases; the others were Patient 19, who had 52% and 50% Ph'+ 
cells on two determinations 10 davs apart prior to initiation of therapy. 
Patient 12, who had 86% initially and 38% after Busulfan, and Patient 21 
who had two pretreatment studies - one showed 100% and the other 26% (see 
below). 
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Treatment Program 
The protocol began with irradiation to the spleen (Fig.l). Radiation 
63 
was delivered through anterior and posterior portals , using Cobalt 60, 
in doses of 50-100 rads three times weekly for a total of 150 to 1950 rads. 
The median dose was 825 rads given over 24 days. Three patients (No.24,26, 
and 12) were not given irradiation as their peripheral blood counts were 
already near normal after 4,8,and 12 weeks of Busulfan. 
After the spleen was reduced in size, and the peripheral blood counts 
were nearing normal levels, irradiation was stopped and the patient was 
allowed to rest until the blood counts stabilized at satisfactory levels. 
The amount of time between completing irradiation and surgery depended on 
the time required for the blood counts to recover, and ranged from a few 
days to two months, with an averaqe of 30 days. At the time of surqery 
the white blood cell counts (WBC) and platelet counts were within the 
normal range in the majority of patients. In three patients there was 
difficulty in controlling the WBC with splenic irradiation. Patient 37, 
whose disease was accelerating at entry (16% blasts) had progression of 
disease while receiving 400 rads, with rapid increase in WBC, marrow blasts, 
and spleen size. He was subsequently treated with chemotherapy and 
splenectomy without control of his disease. The other two patients (No.20 
and 22) initially had good responses to 790 and 590 rads, but within four 
weeks of stopping irradiation the WBC rose rapidly and it was necessary 
to reinstitute irradiation. Blastic transformation occurred in one of 
these patients (No.20) during his second course of irradiation, and in the 
other (No.22) a few weeks after splenectomy. 
Splenectomy was performed on 36 patients; the one patient who was 
not operated on was No. 20. There were no complications during surgery 
and no operative deaths. One patient (No.15) was found to have extensive 
para-aortic node involvement at surgery and shortly thereafter developed 
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52 
extramedullary blastic transformation in his peripheral lymph nodes . He 
was withdrawn from the protocol and given other treatment, but his marrow 
became blastic six months later. Another patient (No.35) was found to have 
a blastic marrow after recovery from surgery and she was similarly given 
other therapy. Complications during the postoperative period included 
a pulmonary embolism eight days after surgery in one patient (No.13) when 
g 
his platelet count was over 1000 x 10 /l. One patient developed a wound 
infection, and two had episodes of gastrointestinal bleeding postoperatively; 
the sites of bleeding were not determined. All recovered completely. 
Chemotherapy was begun after recovery from surgery, usually about one 
month later, in the 32 patients who remained in the "chronic" phase. The 
protocol was discontinued in the 5 patients who had already undergone blastic 
transformation and they received other chemotherapy. In most cases, the 
WBC remained stable postoperatively, but three patients (No.13,18,25) required 
Hydroxyurea in the postoperative period to control rapidly rising WBC until 
they had recovered from the operation and could tolerate more intensive 
chemotherapy. Postoperative thrombocytosis occurred to >500 x 10 /I in 
g 
13 patients and to >1000 x 10 /I in 9 others. Ara-C was given (3.0 mg/kg i.v.) 
with TG (2.5 mg/kg p.o.) every 24 hours to the first few patients, and later 
every 12 hours for the majority of patients. The patients were treated 
fin 
similarly to those with AML on the L-6 Protocol , but not so intensively 
as to cause severe marrow hypoplasia. Patients usually received three 
courses of Ara~C and TG, each time in sufficient dosage to cause moderate 
marrow hypocellularity, with rest periods of 3-4 weeks between courses. 
Immediately following the last course of Ara-C and TG most of the 
patients (24/32) were given L-Asparaginase (E.coli) at 200 IU/kg i.v. 
three times a week for six doses. 
The choice of treatment at the conclusion of the intensive part of 
the protocol depended on the chromosome response. Several patients who 
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initially showed a reduction of Ph' + cells in the marrow with subsequent 
return to Ph'+ predominance were given additional courses of intensive 
chemotherapy in an attempt to re-induce a response, either at the end 
of the protocol or durinq maintenance. Three of these patients (No.6,11,12) 
received Daunorubicin and Ara-C, and two of them (No.6,11) were treated 
to severe marrow hypoplasia. In an attempt to continue suppression of the 
Ph' + population in the responders, therapy was continued with the 
maintenance part of the L-6 Protocol for AML, which consists of rotating 
courses of multiple drugs as previously described^0 and as outlined in 
Figure 2. In cases in which there had been no significant decrease in the 
percentage of Ph'+ cells or in whom attempts to re-induce a response had 
failed. Hydroxyurea was given and the dosage was adjusted according to 
the results of weekly blood counts (usually 20 to 40 mg/kg per day as a 
single dose). Maintenance therapy was continued indefinitely until blastic 
transformation or acceleration of the disease dictated a change to more 
aggressive treatment. Several patients required additional treatment with 
Thiotepa and/or Melphalan to reduce excessively high platelet counts which 
could not be controlled with Hydroxyurea. 
Evaluation of Chromosome Response 
Before and after each phase of the protocol, bone marrow was aspirated 
for evaluation of cellularity and the differential count and analyzed for the 
presence of the Phr chromosome, in the Bone Marrow and Cytogenetics 
laboratories at Memorial Hospital. Whenever possible, 25 to 50 marrow 
metaphases were counted. Responses were arbitrarily considered significant 
only if the percentage of Ph'+ metaphases decreased to less than 1/3 of 
the value obtained just prior to starting the L-5 Protocol. 
Leukocyte alkaline phosphatase (LAP) scores were not followed serially 
in most patients, and were not used as criteria for response. Only a few 
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patients were studied for terminal deoxynucleotidyl transferase activity 
at blastic transformation, as this test was not available during the 
major part of the study. 
RESULTS 
Survival 
The median survival of the 37 patients from diagnosis is 50 months 
(Figure 3). Fourteen patients are alive, all in the chronic state at 
17 to 107 months after diagnosis, as of January 1, 1978. Twenty-three 
have died - 19 after blastic transformation at 5 to 61 months after 
diagnosis. Three of the patients who underwent transformation (No.31 ,26,32) 
also developed myelofibrosis; their survivals were 17,34,and 50 months. 
None of the 19 patients with blastic transformation responded satisfactorily 
to subsequent chemotherapy, and their median survival from transformation 
was 3h months. Two patients (No. 18 and 13) died in an accelerated phase 
of the disease at 12 and 40 months; they were thus termed because the 
disease was clearly out of control and poorly responsive to therapy, 
although they did not fully meet our criteria for blastic transformation 
{30% blasts in the blood and 50% in the marrow). The cause of death of 
Patient 34 is unknown, as he died in another country. One patient (No. 11) 
died of lung cancer while his CML was in complete remission, 52 months 
after diagnosis. 
Ph1 Chromosome Response 
Of the 37 patients who began the protocol, five became blastic before 
chemotherapy was begun, one failed to follow the protocol and had protracted 
intervals between phases of treatment, and two others were inevaluable for 

10 
chromosome response because most of their marrow aspirations were inadequate 
for study due to development of myelofibrosis. Of the remaining 29 cases 
evaluable for chromosome response, 12 were considered to have a significant 
reduction in the percentage of Ph' + cells in their marrows (<l/3 of 
baseline value) and 17 did not respond. Transient reduction occurred in 
some of the non-responders, but in no case was the minimum value less than 
50% of baseline, except in Patient 21 who will be described below. The 
lowest percentages of Ph'+ metaphases achieved in each patient are noted 
in Tables 1 and 2. 
The median survival of those patients with reduced populations of Ph'+ 
cells has not been reached as only four have died, but it appears that it 
will be appreciably longer than the 34 month median of non-responders (Fig.3). 
Three of the responders (No.8,10,9) died between 3 and 7 months after 
undergoing blastic transformation, which occurred at 36,45, and 59 months 
after diagnosis, respectively. One responder (No.11) died in remission as 
noted above. The other 8 responders continue in the chronic phase at 
17 to 107 months. 
There was considerable variation in the duration of the Ph1 
chromosome reduction. Reduction lasted<2 months in 3 patients (No.7,8,12), 
2 to 4 months in 5 others (No. 2,3,4,5,9), and was inevaluable in Patient 
10 whose follow-up study was not done for 9 months. One patient (No.l) 
had two periods of reduction of 8 months each (Fig.5), and only two 
patients had a sustained reduction for more than 3 years (No.6,11). 
Reduction was first noted at different points in the protocol: after 
irradiation in two patients (No.7,11), after splenectomy in two others 
(No.4,6),and after the first or second courses of Ara-C and TG in seven 
(Table 3). One other patient (No.5) showed absence of Ph'+ cells after 
treatment with Ara-C and TG, but since no examinations were made after 
irradiation or splenectomy it is not possible to determine at which 
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point the reduction began. 
Two of the above mentioned patients who showed a reduction in Ph'+ 
cells before receiving chemotherapy had the longest duration of response. 
Patient 11 showed 2% Ph'+ cells after completion of the intensive chemo¬ 
therapy and his marrow remained 0-8% for the remaining 42 months of his 
life. Patient 6 maintained 0-2% Ph'+ cells in her marrow for 43 months 
while she received first maintenance L-6 therapy and later Hydroxyurea. 
At her request, all therapy was then discontinued; her marrow metaphases 
were 16% Ph'+ at that time. Subsequently, the percentage of Ph'+ cells 
gradually increased to 82% over a period of 10 months, and later to 
100%. However, she remained clinically well and required no treatment 
for 31 months after stopping chemotherapy, at which time her WBC rose 
9 9 from around 30 x 10 /I to nearly 100 x 10/1. Hydroxyurea was again 
initiated with a satisfactory response of the WBC, but her marrow 
remains 100% Ph'+ at 107 months after diagnosis. 
The responses first noted after Ara-C and TG were all of short 
duration; in five of the seven patients, the majority of marrow cells 
were again Ph'+ by the end of the intensive part of the protocol. In 
four of these patients (No. 1,8,9,12) an attempt was made to re-induce 
a response with additional intensive treatment. This was successful 
transiently in three (No. 1,9,12). The best response was in Patient 1 
whose marrow remained consistently negative for over 8 months after the 
first course of Ara-C and TG, after which Ph'+ cells reappeared in the 
marrow while he continued on Hydroxyurea. The Ph'+ cells did not 
diminish on retreatment with Ara-C and TG, but largely disappeared for 
another 8 months after institution of the L-6 maintenance regimen. 
Response was never noted later than the Ara-C and TG phase of the 
protocol, unless re-induction was attempted. Eleven of the twelve patients 
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who showed reduction received L-Asparaginase, but in all cases it was 
given after the initial decrease had been demonstrated, and in four of 
these the Ph* marker had already reappeared (Table 3). L-Asparaginase 
did not effect reduction in any of the patients. The maintenance therapy 
did not result in reduction except in the case of Patient 1 who showed 
a second reduction after starting the L-6 maintenance as noted above. 
In addition to the 12 patients who responded, there were two 
"non-responders" with significant numbers of Ph' negative cells, but in 
neither was this attributable to the L-5 Protocol. Patient 21 had two 
studies done prior to receiving splenic irradiation - one showed 100% 
Ph'+ metaphases of 11 counted, and the other 26% of 19. He had received 
no chemotherapy and was receiving only an (unidentified) anticoagulant 
after a myocardial infarction. After receiving a total of 475 rads to the 
spleen his marrow showed 10% Ph‘+ cells of 19 scored, but after 
splenectomy the marker was found in 88% and there was no change 
thereafter. Another patient (No.19) who had about 50% Ph'+ cells on 
repeated studies prior to any treatment, continued to show similar 
proportions of Ph'+ and Ph'- cells in the marrow throughout the L-5 
Protocol, and at its completion there were still 36% Ph'+ cells in the 
marrow. His blood counts remained stable with very little treatment 
except intermittent Hydroxyurea for the next 2% years, but the 
percentage of Ph1+ cells in the marrow gradually increased to nearly 
100%. He has remained clinically well with his disease under control 
on Hydroxyurea 43 months after diagnosis, with nearly all marrow meta¬ 
phases demonstrating the Ph1 marker. 
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Factors Which May Influence Response 
Among possible variables which might predict a favorable prognosis 
for survival or loss of the Ph1 marker, it appears that the size of the 
spleen at diagnosis may be important. Measurements of the spleen size on 
palpation at diagnosis were available for 34 patients. Sixteen had 
relatively small spleens (<7 cm.below the left costal margin) at 
diagnosis, whereas the other 18 had larger spleens (>10 cm.). The 
median survivals of the two groups are similar at the present time: 
44+ months in the former group and 37 months in the latter group. 
However, 63% of the patients with small spleens are still alive, and 
the eventual median survival of this group will probably be appreciably 
longer than than that of the larger-spleer. group in which only 22% of 
patients are alive. 
It is noteworthy that 8 of the 12 patients with Ph' chromosome 
reduction had small spleens at diagnosis (Table 1), and their diseases 
appeared to be slowly progressive. Additionally, in three of these 
patients (No.1,2,6) the WBC and platelet counts remained stable at moderate 
levels or rose only very gradually for many months before the institution 
of any treatment. This group with small spleens and indolent disease 
included the 3 patients with the longest chromosome response. Seven 
of the eight responders with small spleens are still alive; the only 
death resulted from an unrelated carcinoma (No.11). Four of the 
responders had large spleens at diagnosis (Table 1). The duration of 
chromosome response was very brief in all of these patients and in 
three of them the disease underwent blastic transformation and they died. 
At the time of beginning the protocol there was a total of 25 
patients with small spleens because some patients who had large spleens 
when diagnosed had responded to chemotherapy before coming to Memorial 
Hospital. This group with small spleens had an appreciably better 
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response; their median survival is 45+ months with 48% still alive, 
compared to 29 months with only 16% still alive for the 12 patients 
with larger spleens, half of whom had received no prior treatment. 
Of the 25 patients with small spleens, 22 were given splenic 
irradiation (the other three were considered to have had adequate 
control of spleen size and WBC following Busulfan). In reviewing this 
study it became evident that these 22 patients had received a higher 
dose of irradiation per gram of splenic tissue than the group with 
larger spleens. The median dose in the former group was 875 rads 
(range 200-1550 rads), compared to a median dose of 600 rads (150- 
1950 rads) for the 12 with larger spleens. The median weight of the 
24 spleens in the small-spleen group was 318 grams and that of the 
larger spleens was 795 grams (one of the patients in the former group 
did not undergo splenectomy). It is interesting to note that the 
four patients with larger spleens who received higher amounts of 
irradiation ( 875 rads) had smaller spleen weight (525g v. 930g) and 
longer survival than those who received less irradiation (46 v. 25 months). 
There was no correlation between pretreatment WBC level and amount of 
irradiation. The amount of irradiation received depended on the rate 
at which the WBC and spleen size decreased and the appraisal of the 
examining physician. 
These findings suggest a correlation of small spleen size at 
diagnosis with longer survival and greater probability of Ph' chromosome 
reduction; however, as is evident from examination of Table 2, some 
patients with small spleens failed to show a reduction in Ph'+ cells. 
The dose of splenic irradiation may also be important, but this study 
was not designed to answer that question and no conclusions can be 
drawn concerning the significance of irradiation dosage. 
Another difference between responders and non-responders was that 
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marked thrombocytosis (>1000 x 10 /l) occurred at some time in the 
protocol in only four patients in the group with Ph' reduction, whereas 
it was frequently observed in the non-responders (16 of 20). The four 
responders were Patients 4,7,8, and 10, and all of these patients had 
only very transient reduction in Ph1+ cells. Platelet counts between 
9 500 and 1000 x 10 /I were observed at some time in most patients in 
both groups and no correlation of this moderate thrombocytosis with 
response can be made. 
In only two cases was thrombocytosis a life-threatening problem. 
The one postoperative pulmonary embolism has already been noted. Another 
patient (No.26) experienced an abrupt rise in platelets to 7000 x 10^/1 
while recovering from the last course of Ara-C and TG, and she developed 
multiple pulmonary emboli and cardiac arrest. She was successfully 
resuscitated, and with chemotherapy her platelet count was reduced to 
g 
357 x 10/1. She lived another 2 years before her death due to 
myelofibrosis and megakaryocytic leukemia with massive liver involvement. 
One other patient. No.6, who was a responder, had a thrombotic 
complication while on the protocol, but it was not related to thrombo¬ 
cytosis. About two months after completing the intensive phase of 
chemotherapy, she developed thrombophlebitis of an iliac vein and 
pulmonary emboli while on the L-6 maintenance arm of the protocol. 
g 
Her platelet count remained between 180 and 350 x 10/1. She 
eventually underwent plication of the inferior vena cava and had no 
further complications until 6 years later when she developed thrombo¬ 
phlebitis of the other iliac vein; on this occasion the platelet count 
9 
was around 500 x 10/1. The thrombophlebitis responded to conservative 
therapy. 
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DISCUSSION 
Analysis of the L-5 Protocol has shown that: 1) A significant 
reduction in the Ph'+ population is possible in a certain number or cases 
(32% in this study); 2) This reduction occasionally can be achieved by 
splenic irradiation followed by splenectomy as well as by chemotherapeutic 
treatment; 3) Severe marrow hypoplasia is not required; 4) The reduction 
is usually transient and difficult to maintain for more than a few 
months; 5) The reduction may sometimes be re-induced by further 
intensive treatment with Ara-C and TG or Daunorubicin and Ara-C, but 
not by L-Asparaginase or Hydroxyurea in conventional dosages; 6) The 
reduction of the Ph'+ population most often occurs in patients with 
small spleens and slowly progressive disease at the time of diagnosis, 
and it is in this group that duration of response is longest; 7) Patients 
showing a reduction may survive longer than those who do not; it is not 
known whether or not this longer survival is related to treatment with 
the L-5 Protocol, because it is quite possible that such patients with 
slowly progressive or highly responsive disease might also live longer 
with less intensive treatment; 8) Although the 50 month median survival 
for all patients treated with the L-5 Protocol is longer than that of the 
/ ,44 Memorial Hospital historical control series (31 months) , it cannot be 
concluded that the L-5 Protocol is responsible for prolonging survival 
because the patients entered on this protocol were a selected group in 
that some patients with early blastic transformation were excluded. 
Moreove v; uni i ke the historical series, only Ph'+ patients were included 
in the L-5 study and they are known to have a longer survival than 
patients with Ph1 negative CML. 
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Current Treatment Protocols for Early CML 
There have been seven other series reported in which splenectomy was 
performed in early CML^-^ , including more than 150 comparable patients. 
68 All were prospective studies except that of Didolkar et al. All or 
most of the patients in each series were Ph' + , and most of the 
operations were performed within a year of diagnosis. Median survivals 
have been reached in three studies and they were 40 months^, 43 months65, 
and 44 months from diagnosis. These median survivals are comparable 
to the 50 month median in the L-5 series. The median survival times 
for the other series have not been established, but two were reported to 
be on-going at 30+ months^ and 36+ months6*^. It is thus likely that 
all studies will show similar median survival times of between 3 and 4 
years, and we can conclude that early splenectomy in CML does not 
appreciably extend survival. The incidence of blastic transformation was 
reported for only two of these series65,and it was 100% and 76%. 
Median survival from transformation was 2 and 4 months, respectively, 
which is similar to the 3^ months found in the L-5 series. 
In almost all cases, early splenectomy was relatively free of 
serious complications and probably beneficial in preventing late 
complications associated with massive splenomegaly. Operative mortality 
65 66 
was reported by three groups, from infection in 17% , and 2% of 
68 patients, and from bleeding in 9% . As in this study, there were no 
operative deaths in three other series6^*6^’6^. Operative morbidity 
varied,from 12% to 34% in the 3 studies in which it was reported6^ ,66 ’ 6^, 
as did the seriousness of the morbidity observed. Postoperative 
q 67 cc 
thrombocytosis to levels over 1000 x 10 /I was reported in 16% , 33% , 
54% and a "majority"66 of patients in the series in which platelet 
counts were recorded. The median spleen weight at operation varied as 

18 
68 did the choice of pre-operative chemotherapy. Didolkar et al. reported 
mean spleen weights in chronic (1408 g) and blastic (1830 g) cases. 
The chronic cases had received Busulfan, 6-Mercaptopurine, or 
Hydroxyurea, and the operation was carried out when the disease was 
rr 
out of control. Tura et al. reported a median spleen weight of 906 grams 
in patients who had received Hydroxyurea and were not in remission. 
r-j 
Ihde et al. found the median spleen weight to be less than 500 grams 
in patients who were in "remission" from Busulfan. 
Chemotherapeutic regimens varied in the series of splenectomized 
patients. Most groups relied on "conventional" treatment with Busulfan, 
64-69 Dibromomannitol, or Hydroxyurea prior to surgery , and the study by 
68 Didolkar et al. included some who had also received splenic irradiation. 
Three groups employed intensive antimetabolite therapy at various points 
64~72 66 69 in their protocols: 6-Thioguanine , Ara-C , and Ara-C and TG . 
The final results of these studies have not been reported. The 
69 preliminary report by Fuscaldo et al. suggests that this approach may 
improve survival, as the only three deaths in the group of 16 were at 
5, 5%, and lh years. 
Only three of these reports^included evaluation of 
65 
chromomsome response to therapy. Schwarzenberg et al. concluded that 
the Ph'marker "persisted" and Spiers noted that in a group of 17 patients 
treated intensively with Thioguanine prior to splenectomy all maintained 
100% Ph'+ marrows72. However, in the group reported by Fuscaldo et al.^ 
and Brodsky et al.7^ at least 2 of 16 patients have shown a reduction in 
Ph‘+ cells to date. One had a decrease from 100% to 13% Ph'+ metaphases 
after splenectomy and another showed a reduction from 67% to 16% after 
cell cycle-specific chemotherapy 
The seven prospective early splenectomy protocols are similar with 
regard to basic treatment approach and probable ultimate median survival. 
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Of the 7 early splenectomy series, the L-5 study is one of only two in 
which Ph'+ population reduction was apparent. The reasons for this are 
not clear. However, as has been noted, the duration of repopulation of 
the marrow with Ph' negative cells was short in some of the patients, 
and might have been missed if frequent serial cytogenetic examinations 
had not been performed. It seems possible that similar instances of 
transient repopulations with Ph' negative cells might have occurred in 
some of the other series but were not observed because of infrequent 
examinations after treatment. In the L-5 series there was,in addition,a 
relatively low operative morbidity (11%), a low incidence of post - 
operative thrombocytosis to levels above 1000 x 10 /I (23%), and the 
median spleen weight (358 g) was smaller than in the other series noting 
it. The principal difference between the L-5 and other protocols was 
that splenic irradiation rather than chemotherapy preceded splenectomy. 
It is possible that this treatment achieved better control of the 
disease and played a role in the decrease in the Ph' cell populations 
42 
which we observed. The Medical Research Council study concluded that 
splenic irradiation was not as effective as Busulfan in terms of 
extending survival, but the timing and doses of irradiation were not 
consistent in the irradiated group and the patients received various 
chemotherapeutic agents in addition. The role of irradiation as primary 
73 treatment is currently being investigated by Jacobs et al. 
74 Smalley et al. treated a series of selected patients intensively 
with Ara-C and TG after their diseases had been brought under good 
control with Busulfan; they had nearly normal blood counts and no 
splenomegaly at the time of beginning Ara-C and TG. Splenectomy was 
not done. Two of the 10 evaluable patients showed a significant 
reduction in Ph'+ cells. One showed complete absence of the Ph' marker 
on one determination after 3 months of treatment, with 11% after 6 courses. 

20 
She was alive at 6 years after diagnosis. The other patient showed 
only 7% Ph'+ cells after the 6th course, which is particularly interesting 
because his marrow had been consistently 100% Ph'+ through five courses, 
as was the study following the 7% determination. 
Although overall median survival may not have been significantly 
prolonged by the aggressive approach that all these studies demonstrate, 
the possibility remains that survival may be longer in those patients 
who show evidence of decrease in the percentage of the Ph'+ metaphases 
in their marrows, as suggested by the occasional reports prior to these 
25 32-35 69 
current studies * , the preliminary reports of Fuscaldo et al. 
74 
and Smalley et al. and the results of the L-5 Protocol. 
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Figure 1 
L-5 PROTOCOL 
SPLENIC IRRADIATION 
SPLENECTOMY 
y 
ARABINOSYLCYTOSINE + 6-THIOGUANINE 
x 3 courses 
L-ASPARAGINASE 
RE-INDUCTION ATTEMPT : HYDROXYUREA 
ARABINOSYLCYTOSINE 
6-THIOGUANINE 
or 
DAUNORUBICIN 
ARABINOSYLCYTOSINE 
L-6 MAINTENANCE 
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Figure 2 
L-6 MAINTENANCE PROTOCOL 
VCR BCNU CTX 
t t T T 
MTX HU 
rest 
10-14 d 
rest 
10-14 d 
rest 
14-21 d 
rest 
14-21 d 
recycle 
J_I_I_1 ..J 
1 15 30 45 60 
day of Rx 
VCR = Vincristine 0.03-0.04 mg/kg i.v. x 1 
MTX = Methotrexate 10 mg p.o. x 4 d 
BCNU = 1,3-bis (2-chloroethyl)-l-nitrosurea 1-2 mg/kg i.v. x 1 
TG = 6-Thioguanine lOmg/kg p.o. x 4 d 
CTX = Cyclophosphamide 10-20 mg/kg i.v. x 1 
HU = Hydroxyurea 60-80 mg/kg p.o. x 4 d 
DNR = Daunorubicin 0.5-1.0 mg/kg i.v. x 1 
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Figure 3 
L-5 PROTOCOL : SURVIVAL 
Symbols indicate last follow-up of living patients (1/1/78) 
□ Whole group (37 pts, 14 alive) 
O Non-responders (25 pts, 6 alive) 
A Responders (12 pts, 8 alive) 
Survival curves calculated by the Kaplan-Meier product 
limit method(76). Application of the logrank test(76) 
comparing survival patterns of responders and non-responders 
yielded p=0.005. Median survival times are 50 months for 
the whole group, 34 months for non-responders, and has not 
been reached for responders. 
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